{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:58:58Z","timestamp":1791021538898,"version":"4.1.0"},"reference-count":68,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2012,3,20]],"date-time":"2012-03-20T00:00:00Z","timestamp":1332201600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"DOI":"10.1371\/journal.pmed.1001189","type":"journal-article","created":{"date-parts":[[2012,3,22]],"date-time":"2012-03-22T15:11:00Z","timestamp":1332429060000},"page":"e1001189","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":86,"title":["Publication Bias in Antipsychotic Trials: An Analysis of Efficacy Comparing the Published Literature to the US Food and Drug Administration Database"],"prefix":"10.1371","volume":"9","author":[{"given":"Erick H.","family":"Turner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Knoepflmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Shapley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,3,20]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"e3081","DOI":"10.1371\/journal.pone.0003081","article-title":"Systematic review of the empirical evidence of study publication bias and outcome reporting bias.","volume":"3","author":"K Dwan","year":"2008","journal-title":"PLoS ONE"},{"key":"ref2","first-page":"MR000006","article-title":"Publication bias in clinical trials due to statistical significance or direction of trial results.","volume":"2009","author":"S Hopewell","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1745-6215-11-37","article-title":"Reporting bias in medical research\u2014a narrative review.","volume":"11","author":"N McGauran","year":"2010","journal-title":"Trials"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0895-4356(00)00242-0","article-title":"Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature.","volume":"53","author":"JA Sterne","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1371\/journal.pmed.0010060","article-title":"A taxpayer-funded clinical trials registry and results database.","volume":"1","author":"EH Turner","year":"2004","journal-title":"PLoS Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1371\/journal.pmed.0050217","article-title":"Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation.","volume":"5","author":"K Rising","year":"2008","journal-title":"PLoS Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1371\/journal.pmed.0050191","article-title":"Publication of clinical trials supporting successful new drug applications: a literature analysis.","volume":"5","author":"K Lee","year":"2008","journal-title":"PLoS Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMsa065779","article-title":"Selective publication of antidepressant trials and its influence on apparent efficacy.","volume":"358","author":"EH Turner","year":"2008","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1177\/070674370204700904","article-title":"Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature.","volume":"47","author":"EM Goldner","year":"2002","journal-title":"Can J Psychiatry"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0140-6736(98)07507-2","article-title":"Multiple-informant ranking of the disabling effects of different health conditions in 14 countries. WHO\/NIH Joint Project CAR Study Group.","volume":"354","author":"TB Ust\u00fcn","year":"1999","journal-title":"Lancet"},{"key":"ref11","article-title":"Drugs@FDA: FDA approved drug products [database].","year":"2012"},{"key":"ref12","article-title":"The Freedom of Information Act 5 U.S.C. \u00a7 552, as amended by Public Law No. 104-231, 110 Stat. 3048. FOIA Update, Vol. XVII, No. 4","year":"1996"},{"key":"ref13","first-page":"MR000005","article-title":"Full publication of results initially presented in abstracts.","volume":"2007","author":"RW Scherer","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"ref14","first-page":"1","article-title":"Proposed definition of a primary publication.","volume":"1968","year":"1969","journal-title":"CBE Newsletter November"},{"key":"ref15","first-page":"112","article-title":"Anchoring the BPRS: an aid to improved reliability.","volume":"24","author":"MG Woerner","year":"1988","journal-title":"Psychopharmacol Bull"},{"key":"ref16","first-page":"59","article-title":"The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation.","author":"SR Kay","year":"1989","journal-title":"Br J Psychiatry Suppl"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"c2697","DOI":"10.1136\/bmj.c2697","article-title":"Modified intention to treat reporting in randomised controlled trials: systematic review.","volume":"340","author":"I Abraha","year":"2010","journal-title":"BMJ"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1081\/BIP-120019265","article-title":"Assessing response profiles from incomplete longitudinal clinical trial data under regulatory considerations.","volume":"13","author":"CH Mallinckrodt","year":"2003","journal-title":"J Biopharm Stat"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1592\/phco.29.12.1408","article-title":"Last-observation-carried-forward imputation method in clinical efficacy trials: review of 352 antidepressant studies.","volume":"29","author":"SB Woolley","year":"2009","journal-title":"Pharmacotherapy"},{"key":"ref20","article-title":"Stata statistical software: release 11 [computer program]","year":"2009"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1037\/0033-2909.92.2.490","article-title":"Estimation of effect size from a series of independent experiments.","volume":"92","author":"LV Hedges","year":"1982","journal-title":"Psychol Bull"},{"key":"ref22","doi-asserted-by":"crossref","DOI":"10.4135\/9781412984997","article-title":"Meta-analytic procedures for social research","author":"R Rosenthal","year":"1991"},{"key":"ref23","article-title":"Statistical methods for meta-analysis","author":"LV Hedges","year":"1985"},{"key":"ref24","first-page":"57","article-title":"Fixed effects methods for combining study estimates.","author":"AJ Sutton","year":"2000"},{"key":"ref25","article-title":"Cochrane handbook for systematic reviews of interventions, version 5.1.0.","author":"J Higgins","year":"2011"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"R DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"ref27","first-page":"347","article-title":"Meta\u2013analysis in Stata.","author":"JAC Sterne","year":"2001"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis.","volume":"21","author":"JP Higgins","year":"2002","journal-title":"Stat Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/bmj.39343.408449.80","article-title":"Uncertainty in heterogeneity estimates in meta-analyses.","volume":"335","author":"JP Ioannidis","year":"2007","journal-title":"BMJ"},{"key":"ref30","article-title":"Heterogi: Stata module to quantify heterogeneity in a meta-analysis, revised 2006-01-25 [computer program]. Statistical Software Components S449201","author":"N Orsini","year":"2005"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1097\/JCP.0b013e3181692787","article-title":"Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies.","volume":"28","author":"SG Potkin","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"JPT Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1742-1241.2010.02344.x","article-title":"Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic.","volume":"64","author":"L Citrome","year":"2010","journal-title":"Int J Clin Pract"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/JCP.0b013e318169d4ce","article-title":"Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.","volume":"28","author":"AJ Cutler","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/00004714-199604000-00008","article-title":"ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group.","volume":"16","author":"RL Borison","year":"1996","journal-title":"J Clin Psychopharmacol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s002130050755","article-title":"Ziprasidone 40 and 120 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial.","volume":"140","author":"P Keck","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"ref37","first-page":"213","article-title":"Risperidone: clinical safety and efficacy in schizophrenia.","volume":"28","author":"RL Borison","year":"1992","journal-title":"Psychopharmacol Bull"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1365-2710.1996.tb00030.x","article-title":"Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety.","volume":"21","author":"IR de Oliveira","year":"1996","journal-title":"J Clin Pharm Ther"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jama.290.4.516","article-title":"Registering clinical trials.","volume":"290","author":"K Dickersin","year":"2003","journal-title":"JAMA"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00004714-199302000-00004","article-title":"A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.","volume":"13","author":"G Chouinard","year":"1993","journal-title":"J Clin Psychopharmacol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1176\/ajp.151.6.825","article-title":"Risperidone in the treatment of schizophrenia.","volume":"151","author":"SR Marder","year":"1994","journal-title":"Am J Psychiatry"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.","volume":"58","author":"SR Marder","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/01.pra.0000367774.11260.e4","article-title":"Biases in medication prescribing: the case of second-generation antipsychotics.","volume":"16","author":"M Makhinson","year":"2010","journal-title":"J Psychiatr Pract"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1176\/appi.ajp.163.2.185","article-title":"Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics.","volume":"163","author":"S Heres","year":"2006","journal-title":"Am J Psychiatry"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.mp.4002136","article-title":"How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials.","volume":"14","author":"S Leucht","year":"2009","journal-title":"Mol Psychiatry"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/bmj.326.7400.1171","article-title":"Evidence b(i)ased medicine\u2014selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications.","volume":"326","author":"H Melander","year":"2003","journal-title":"BMJ"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0006-3223(00)00973-2","article-title":"Consistency of atypical antipsychotic superiority to placebo in recent clinical trials.","volume":"49","author":"SW Woods","year":"2001","journal-title":"Biol Psychiatry"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1371\/journal.pmed.0050045","article-title":"Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration.","volume":"5","author":"I Kirsch","year":"2008","journal-title":"PLoS Med"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.2009.1943","article-title":"Antidepressant drug effects and depression severity: a patient-level meta-analysis.","volume":"303","author":"JC Fournier","year":"2010","journal-title":"JAMA"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/bmj.39510.531597.80","article-title":"Efficacy of antidepressants.","volume":"336","author":"EH Turner","year":"2008","journal-title":"BMJ"},{"key":"ref51","article-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.biopsych.2005.09.014","article-title":"Size of treatment effects and their importance to clinical research and practice.","volume":"59","author":"HC Kraemer","year":"2006","journal-title":"Biol Psychiatry"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00406-008-0812-0","article-title":"Do effectiveness (\u201creal world\u201d) studies on antipsychotics tell us the real truth?","volume":"258","author":"H-J M\u00f6ller","year":"2008","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.schres.2006.06.013","article-title":"Neurocognitive performance and negative symptoms: are they equal in explaining disability in schizophrenia outpatients?","volume":"87","author":"V Villalta-Gil","year":"2006","journal-title":"Schizophr Res"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.2009.973","article-title":"The need for improved access to FDA reviews.","volume":"302","author":"AB O'Connor","year":"2009","journal-title":"JAMA"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1056\/NEJMp1005202","article-title":"Transparency at the Food and Drug Administration.","volume":"362","author":"AK Asamoah","year":"2010","journal-title":"N Engl J Med"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1001\/archpsyc.1997.01830180067009","article-title":"Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.","volume":"54","author":"JG Small","year":"1997","journal-title":"Arch Gen Psychiatry"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0006-3223(97)00190-X","article-title":"Multiple fixed doses of \u201cSeroquel\u201d (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.","volume":"42","author":"LA Arvanitis","year":"1997","journal-title":"Biol Psychiatry"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.","volume":"63","author":"JM Kane","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","article-title":"Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.","volume":"60","author":"SG Potkin","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jpsychires.2007.05.002","article-title":"A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg\/day for the treatment of patients with acute exacerbations of schizophrenia.","volume":"41","author":"JP McEvoy","year":"2007","journal-title":"J Psychiatr Res"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.schres.2006.09.012","article-title":"Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.","volume":"90","author":"J Kane","year":"2007","journal-title":"Schizophr Res"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.biopsych.2007.01.017","article-title":"Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.","volume":"62","author":"SR Marder","year":"2007","journal-title":"Biol Psychiatry"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.schres.2007.03.003","article-title":"Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.","volume":"93","author":"M Davidson","year":"2007","journal-title":"Schizophr Res"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1176\/appi.ajp.160.6.1125","article-title":"Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.","volume":"160","author":"JM Kane","year":"2003","journal-title":"Am J Psychiatry"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0893-133X(95)00069-P","article-title":"Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.","volume":"14","author":"CM Beasley","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF02245617","article-title":"Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial.","volume":"124","author":"CM Beasley","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0893-133X(98)00090-6","article-title":"Ziprasidone 80 mg\/day and 160 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group.","volume":"20","author":"DG Daniel","year":"1999","journal-title":"Neuropsychopharmacology"}],"container-title":["PLoS Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pmed.1001189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T22:22:55Z","timestamp":1561501375000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1001189"}},"subtitle":[],"editor":[{"given":"Peter C.","family":"G\u00f8tzsche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,3,20]]},"references-count":68,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2012,3,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1001189","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,20]]}}}